BBB seminar: Christel Herold-Mende
Glioma and immunotherapy: from bench to bedside
Division of Experimental Neurosurgery, Department of Neurosurgery, University of Heidelberg, Germany
Treatment success and survival in glioma patients is still limited, corroborating an urgent need for novel more effective therapies. Just recently immunotherapies have been successful in treatment of other tumor types while in gliomas data from phase III trials have to be awaited. Important for the success of such therapies is a better understanding of suitable antigens, the role of intratumoral immune infiltrates, spontaneous immune responses and how these can be transferred into the clinic. The seminar will introduce our findings about i) novel techniques to identify such antigens and to characterize immune infiltrates, ii) the role of spontaneous anti-tumor T cell responses and iii) the development of a peptide vaccine which is currently being tested in a first round of clinical trials.
Chairperson: Rolf Bjerkvig , Department of Biomedicine